Disease-Modifying Therapies for Companion Animals

Targeting the largest unmet need in companion animal health: slowing osteoarthritis, not just masking its pain.

Based in the south of France and founded in 2026, PawGenX is a preclinical veterinary biotech company supported by the Impulse incubator.

We develop disease-modifying osteoarthritis drugs (DMOADs) for companion animals. Our goal is to slow the structural progression of the disease.

Our pipeline builds on patented academic research, advanced through a translational strategy designed around the realities of veterinary practice.

Why Canine Osteoarthritis

Osteoarthritis is one of the most common chronic diseases in dogs, and a leading cause of pain, lameness and early euthanasia in senior animals.

Current treatments, from NSAIDs to anti-NGF antibodies, only manage symptoms. No approved therapy protects cartilage or slows structural progression. 

A Differentiated DMOAD Pipeline

Two patent-protected programs and an in-house discovery platform, starting with dogs, with potential across companion animal species:

PGX1: a repurposed small molecule targeting inflammatory drivers of joint degeneration, with preventive efficacy validated across preclinical models.

PGX2: a peptide-based therapeutic acting on cartilage homeostasis.

Next-generation platform: species-optimized biologics designed with AI-supported tools, to expand the pipeline across inflammatory diseases in companion animals.

Partnering-Ready Preclinical Design

PawGenX builds preclinical asset profiles and data packages aligned with animal health industry partnering standards, with a focus on species relevance, differentiation, durability and translational confidence.
Efficacy studies are designed with veterinary school partners in client-owned dogs, advancing high-value assets toward strategic licensing.